Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
30 Results for "
PDB 6RWH
" in MedChemExpress (MCE) Product Catalog:
Products (30)
30 Results for "PDB 6RWH" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-P70805
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF11B; Osteoprotegerin; Prev. OPG; Tumor Necrosis Factor Receptor Superfamily, Member 11b; OCIF; Tumor Necrosis Factor Receptor Superfamily Member 11B; Osteoclastogenesis Inhibitory Factor; PDB5; TNF Receptor Superfamily Member 11b; TR1
Species:
Human
Source:
HEK293
2
2 Cited Publications
Cat. No.: HY-P71017
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF11B; Osteoprotegerin; Prev. OPG; Tumor Necrosis Factor Receptor Superfamily, Member 11b; OCIF; Tumor Necrosis Factor Receptor Superfamily Member 11B; Osteoclastogenesis Inhibitory Factor; PDB5; TNF Receptor Superfamily Member 11b; TR1
Species:
Mouse
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-B1040
CAS No.: 19368-18-4
Target:
Research Areas:
Ftaxilide is an anti-ulcer agent. Ftaxilide exhibits notable biological properties, including antibacterial, antioxidant, and anti-tuberculosis activities. Ftaxilide shows weak binding to the Mycobacterium tuberculosis target protein (PDB ID: 1GTV). Ftaxilide can be used in research on irritable bowel syndrome and tuberculosis .
1
1 Cited Publications
Cat. No.: HY-P7053
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF11B; Osteoprotegerin; Prev. OPG; Tumor Necrosis Factor Receptor Superfamily, Member 11b; OCIF; Tumor Necrosis Factor Receptor Superfamily Member 11B; Osteoclastogenesis Inhibitory Factor; PDB5; TNF Receptor Superfamily Member 11b; TR1
Species:
Human
Source:
CHO
1
1 Cited Publications
Cat. No.: HY-P700432
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF11B; Osteoprotegerin; Prev. OPG; Tumor Necrosis Factor Receptor Superfamily, Member 11b; OCIF; Tumor Necrosis Factor Receptor Superfamily Member 11B; Osteoclastogenesis Inhibitory Factor; PDB5; TNF Receptor Superfamily Member 11b; TR1
Species:
Human
Source:
HEK293
Cat. No.: HY-P99238
CAS No.: 2095467-30-2
Target:
Research Areas:
Cat. No.: HY-W009970
CAS No.: 6436-90-4
Target:
Research Areas:
Cat. No.: HY-126531
CAS No.: 663599-04-0
Target:
Research Areas:
DMAC-PDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
Cat. No.: HY-151477
CAS No.: 96068-42-7
SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 main protease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 .
Cat. No.: HY-129366
CAS No.: 2088570-81-2
Target:
Research Areas:
PDB-Pfp is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Cat. No.: HY-151478
CAS No.: 299919-79-2
SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19 .
Target:
Research Areas:
DH-8P-DB is an anticancer candidate and exhibits cytotoxicity against colon cancer cells .
Cat. No.: HY-L052
1,381 compounds
COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.
Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1,381 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.
Cat. No.: HY-153145
CAS No.: 922128-14-1
Target:
Research Areas:
F2276-0104 is a potential PCAF bromodomain (PDB 5FDZ) inhibitor. F2276-0104 is predicted to have good cell permeability and ADME properties. F2276-0104 can be used for cancer-related research .
Cat. No.: HY-153144
CAS No.: 922054-57-7
Target:
Research Areas:
F2276-0106 is a biochemical reagent targeting the PCAF bromodomain (PDB 5FDZ). F2276-0106 is predicted to have good cell permeability and oral absorption, with physicochemical properties consistent with Lipinski's rule of five. F2276-0106 can be used in cancer-related research .
Cat. No.: HY-121946
CAS No.: 35512-29-9
Synonyms: 4-(4-Chlorophenyl)imidazole
Target:
Research Areas:
4-CPI (4-(4-Chlorophenyl)imidazole) is a CYP2B4 inhibitor with an IC50 of 0.11 μM and a Kd of 0.043 μM. The Ks of 4-CPI for cytochrome P450eryF (S93C/C154S mutant) is 9.4 μM, with no allosteric cooperative effect of ligand binding . 4-CPI binds to CYP2B4 at a 1:1 ratio, which induces substantial conformational changes in the enzyme's active pocket to form a closed crystal conformation (PDB:1SUO). 4-CPI can be used to investigate the flexibility of P450 active pockets, protein-ligand binding thermodynamics, and the allosteric mechanisms of P450 .
Cat. No.: HY-153147
CAS No.: 922000-45-1
Target:
Research Areas:
F2276-0008 is a potential PCAF bromodomain (PDB 5FDZ) inhibitor. F2276-0008 is predicted to have good cell permeability and oral absorption. F2276-0008 exhibits a stable C-alpha backbone RMSD and maintains compactness. F2276-0008 can be used for cancer-related research .
Cat. No.: HY-189085
CAS No.: 1186659-59-5
IGF-1R-IN-6 is an IGF-1R inhibitor and a co-crystal ligand in the kinase structure of PDB 3EKK. IGF-1R-IN-6 occupies the kinase binding pocket. IGF-1R-IN-6 can be used in cancer research .
Cat. No.: HY-181116
Anticancer agent 298 is a bi-nuclear Cu(II)-hydrazone complexe. Anticancer agent 298 can bind to the CDK-2 active site (PDB ID: 3IG7) via hydrogen bonds with key amino acid residues. Anticancer agent 298 exerts cytotoxic effects against hepatocellular carcinoma cells, and has lower cytotoxicity against normal human embryonic kidney cells. Anticancer agent 298 can be used for the research of hepatocellular carcinoma .
Cat. No.: HY-P73332
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF11B; Osteoprotegerin; Prev. OPG; Tumor Necrosis Factor Receptor Superfamily, Member 11b; OCIF; Tumor Necrosis Factor Receptor Superfamily Member 11B; Osteoclastogenesis Inhibitory Factor; PDB5; TNF Receptor Superfamily Member 11b; TR1
Species:
Human
Source:
HEK293
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
